Allograft rejection results from the specific recognition by host CD8+ T cells of allogeneic major histocompatibility complex (MHC) molecules on the tissue graft. The specificity of this cellular response is determined by the molecular interaction of the T-cell receptor (TCR) on host T cells with the MHC molecule and its bound ligand on the grafted tissue. To better understand the precise manner by which the TCR interacts with the MHC-peptide complex and how to therapeutically intervene, we have studied the allogeneic response to the mouse class I MHC molecule Ld. In this report, the therapeutic potential of a synthetic peptide derived from the TCR V(88 variable region that predominates in responses to Ld was tested. This V138-derived peptide was found to dramatically and specifically block the in vivo and in vitro allogeneic response to Ld. Furthermore, this specific blocking is not dependent upon the presence ofV,B8+ effector cells nor does the V88 peptide bind to the Ld ligand binding cleft. We propose that this peptide functions as an antagonist, competing with the native TCR for recognition of the Ld molecule.
TCR interacts with the MHC-peptide complex and how to therapeutically intervene, we have studied the allogeneic response to the mouse class I MHC molecule Ld. In this report, the therapeutic potential of a synthetic peptide derived from the TCR V(88 variable region that predominates in responses to Ld was tested. This V138-derived peptide was found to dramatically and specifically block the in vivo and in vitro allogeneic response to Ld. Furthermore, this specific blocking is not dependent upon the presence ofV,B8+ effector cells nor does the V88 peptide bind to the Ld ligand binding cleft. We propose that this peptide functions as an antagonist, competing with the native TCR for recognition of the Ld molecule.
During transplantation or allograft rejection, determinants encoded within the major histocompatibility complex (MHC) of the donor are recognized by T cells of the recipient. This recognition results in a potent immunological response in which the donor cells are rapidly and specifically killed and the allograft is destroyed (1, 2) . It is generally accepted that T cells recognize foreign antigen in the form of peptides bound to selfMHC molecules. However, the molecular basis of T-cell recognition of allogeneic cells remains controversial (e.g., the extent to which alloreactive T cells are peptidespecific). Furthermore, it has been proposed that chronic rejection may result from indirect T-cell recognition of an allogeneic MHC-derived peptide bound to a self MHC molecule (3) . Thus MHC antigens clearly influence the fate of allograft rejection but the precise mechanism(s) remains unclear.
Initial studies analyzing T-cell receptor (TCR) usage during end-stage transplantation rejection episodes resulting from MHC disparities have been conflicting. Whereas certain studies have reported preferential TCR usage in alloreactive responses (4) (5) (6) , other studies found diversified TCR usage (7) (8) (9) . Recently, our laboratory has investigated (6) the allogeneic response to the murine class I MHC molecule Ld and found that T cells carrying TCRs with V(88 variable (V) regions predominate in in vitro and in vivo T-cell responses to Ld. For example, monoclonal antibody (mAb) to V138 was found to specifically and dramatically prolong Ld-disparate skin and heart allografts. This observation afforded us the unique opportunity to test the efficacy of using TCR-derived peptides to block the alloreactive response.
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The use of peptide to manipulate the immune response was greatly facilitated by the elucidation of the three-dimensional structure of the MHC class I molecule (10) . The crystal structure of class I molecules revealed al and a2 regions that fold to form a peptide binding cleft and helical regions that provide potential contact sites for the TCR (11) . In addition, for certain murine models of autoimmune disease, it has been possible to identify TCR gene usage of the causative T cells (12) . With this information, in vivo therapies using synthetic peptides have been successfully employed (13) . However, to our knowledge, similar strategies have previously not been used in transplantation.
In this report we use a TCR-derived peptide to specifically block the in vitro and in vivo immune response to Ld alloantigens. Our Competitive Inhibition Assay. Generation of MCMVspecific CTLs was performed as described (23) . Competitive inhibition assays were performed as described (24) by preincubating 51Cr-labeled P815 (H-2d) target cells for 1 h at 37°C with 100 ,uM competitor peptide in the presence or absence of 100 uM antigenic peptide, followed by analysis in a standard 51Cr-release assay.
RESULTS

Synthetic VI8 TCR Peptide Specifically Prolongs Ld_
Disparate Skin Allograft Survival. To determine whether a TCR-derived synthetic peptide could prolong allograft survival, mice of the Ld-loss strain dm2 (25) were injected subcutaneously with the V,B8 peptide every 3 days until complete allograft rejection occurred. Peptide-treated dm2 mice were engrafted with two skin allografts, Ld-disparate BALB/c skin and H-2b-disparate C57BL/6 skin. As shown in Fig. 1A , the V,B8 peptide treatment prolonged the Lddisparate skin allografts =10 days beyond control mice injected with saline or the V1314 peptide. In contrast, V,B8 peptide had no significant effect on H-2b-disparate allograft rejection (data not shown).
To more rigorously assess the MHC specificity of the V,B8 peptide treatment, the peptide was tested in a donorrecipient strain combination differing by only Dk or Ld. As shown in Fig. 1B , the Dk-disparate skin allografts were rejected by V,B8-peptide-treated and control mice in similar time fashions, whereas Ld-disparate skin allograft survival was significantly prolonged in V,38-peptide-treated mice. Thus, the prolongation of Ld-disparate allografts by the V38 peptide is substantial in duration and MHC-specific. Lymphocytes from peptide-treated mice showed no reduction in V,B8 expression, indicating that graft prolongation did not result from depletion of VP38 Ld-reactive T cells. In addition, serum from peptide-treated mice did not contain antibody capable of blocking CTL recognition of Ld, indicating that peptide did not induce anti-idiotypic antibodies capable of down regulating the allogeneic response to Ld (data not shown).
V.38 TCR Peptide Abrogation of the in Vitro Allogeneic
Immune Response to Ld. To extend the above findings with allograft survival to in vitro assays, the V,B8 peptide was tested for its ability to block cytotoxicity of dm2 spleen cells stimulated with BALB/c cells in vitro. When Vf88 peptide was added throughout the entire culture period, as much as 80% inhibition of the response to Ld was seen (Fig. 2) (16) (17) (18) with the Ld ligand MCMV, while there was no induction of H-2Kk molecules with the MCMV peptide. In contrast, cell surface expression of Ld was not induced after culture with the V,B8 peptide. As expected no induction of H-2Kk was observed. Thus the V,B8 peptide does not bind to the ligand binding groove of Ld, as measured by increased cell surface expression, as occurs with all other known ligands to Ld (28) .
The second assay employed to determine whether the V/88 peptide binds the Ld ligand binding site was a peptide competition assay using a CTL clone specific for the MCMV peptide bound to Ld (23) . As shown in Fig. 5 , the LCMV peptide, a known Ld ligand (16) , showed significant inhibition at both 10 ,uM and 100 ,uM. In contrast, 100 AM Vf38 peptide or 100 ,uM V814 peptide showed no inhibitor activity. Thus together with the inability to induce Ld cell surface expression, these data clearly demonstrate that the V,B8 peptide does not compete for the binding cleft of Ld. These findings indicate that the ability of the V,B8 peptide to inhibit alloreactivity to Ld does not reflect the displacement of endogenous ligands involved in allorecognition nor does the V,88 peptide function as an antagonistic Ld ligand capable of specifically down regulating T-cell function (29) . DISCUSSION Allograft rejection remains a formidable problem in modem medicine. Transplantation recipients continue to receive lifelong high-dose nonspecific immunosuppression that renders them susceptible to a variety of infectious and neoplastic complications. Peptide therapies could represent a means by which the host response to allografted tissue could be specifically blocked and thus the number of posttransplantation complications could be decreased. Specific blockage of the alloreactive response requires intervention into the interaction between the TCR of host T cells and MHC molecules of the transplant. In the absence of the TCR crystal structure, the V regions of the TCR have been modeled based on structural similarities with immunoglobulin. Based on this modeling the V domains of the two molecules have been predicted to display similar folding. Furthermore, the three hypervariable regions of the immunoglobulin [complementarity-determining regions 1-3 (CDR1-3)] known to form the principal contact points of immunoglobulin with antigen are located at equivalent locations in the TCR. Given these similarities between TCR and immunoglobulin, Davis and Bjorkman (11) 10 ,uM LCMV (A), 100 ,uM V188 (m), or 100 ,uM V,314 (*) as described (24) . The target cells were washed and assayed for recognition by a CTL clone specific for Ld plus MCMV in a 4-h 51Cr-release assay.
helical portions of the al/a2 domains of the MHC class I molecule (11) and the CDR3 region of the TCR interacts with the bound peptide. In the context of this model, strategies have been employed to specifically block TCR recognition of MHC by using synthetic peptides derived from TCR V regions implicated in autoimmune responses (12, 13) .
The rodent autoimmune demyelinating disease, experimental autoimmune encephalomyelitis (EAE), was the first immune response in which the therapeutic potential of a synthetic TCR peptide was evaluated. It is recognized that in EAE self MHC molecules bind and present the self antigen myelin basic protein, followed by preferential recognition of these molecules by V388+ myelin basic protein-reactive T cells, resulting in demyelination and paralysis (12, 13) . The initial V,38 TCR-derived peptide studies demonstrated that EAE could be prevented or reversed by treatment with a synthetic Vf38 peptide (12, 13) . Mechanistic studies in EAE suggest that the V,l8 peptide binds to an MHC molecule (presumably class I) and induces a regulatory mechanism that selectively down regulates V,88+ T cells (30) .
Our present findings clearly demonstrate that specific alloreactivity to the murine MHC class I molecule Ld, which has been shown to predominantly use V,88+ T cells (6) , can be abrogated by in vitro treatment with the V,8 peptide.
Additionally, in vivo treatment significantly prolongs the survival of Ld-disparate skin allografts without altering the immune response to other MHC class I molecules, demonstrating that this immunological intervention is MHCspecific. Our mechanistic studies show that these findings are not due to regulatory cells or anti-idiotypic antibodies and are not dependent upon V,B8+ T cells. This would imply that V,B8
peptide is acting by a mechanism distinct from that proposed for EAE. Furthermore, the lack of ligand binding site competition indicates that the replacement of dominant alloreactive peptides is not occurring. However, it remains possible that the V,38 peptide binds an alternate region on Ld molecules such as the al/a2 helical portion. It has been predicted that this V,88 peptide is capable of attaining a secondary structure reflective of the native CDR2 region from which it was derived (31). In addition, based on computer modeling, it has been suggested that the CDR2 region of the TCR interacts with the al/a2 helical portions of the MHC molecule (11) . Given the validity of these assumptions, it is attractive to speculate that the V,88 peptide binds Ld, in a fashion similar to an intact TCR, and competes effectively for interaction with Ld. Such a mechanism is intriguing in light of the observation that peptides derived from the a2 region of HLA-A2 (32) or H-2Kb (33) molecules can also block in vitro allorecognition. However, the efficacy of these peptides in vivo is unknown. It is possible that both the MHC and TCR peptides could function as respective antagonists blocking the interaction of the TCR with the MHC. Indeed, in preliminary studies, we have found that the immune response to Ld can be abrogated by the in vivo administration of a peptide from the a2 region of Ld. These studies raise the possibility that peptide therapies can be customized to individual MHC molecules and used to specifically inhibit allorecognition.
